Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 4:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 1,662 matching trials from the live ClinicalTrials.gov search.
Conditions
Diabetes Mellitus, Type 1
Interventions
TOL-3021, TOL-3021 Placebo
Biological · Other
Lead sponsor
Tolerion, Inc.
Industry
Eligibility
12 Years to 35 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Miami, Florida
Completed Not applicable Interventional Results available

Shared Medical Decision Making in Pediatric Diabetes

NCT02496156
Conditions
Type 1 Diabetes Mellitus
Interventions
Usual Clinical Practice, Shared Medical Decision Making
Behavioral
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
11 Years to 17 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Continuous Glucose Monitoring System
Device
Lead sponsor
Senseonics, Inc.
Industry
Eligibility
14 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
4
States / cities
Escondido, California • Idaho Falls, Idaho • San Antonio, Texas + 1 more
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC), Hepatocellular Carcinoma (HCC), Colorectal Cancer (CRC), HER2 Negative Breast Cancer, Cutaneous Melanoma, Renal Cell Carcinoma (RCC)
Interventions
GI-102 subcutaneous (SC), GI-102, doxorubicin, paclitaxel, bevacizumab, eribulin, trastuzumab deruxtecan (T-DXd), pembrolizumab
Drug
Lead sponsor
GI Innovation, Inc.
Industry
Eligibility
18 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more
Conditions
Type 1 Diabetes
Interventions
Glucagon Nasal Powder [Baqsimi]
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
1 Year to 4 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Jacksonville, Florida • Boise, Idaho • Indianapolis, Indiana + 5 more
Completed Not applicable Interventional Results available

PRISM for Adolescents With Type 1 Diabetes

NCT03847194
Conditions
Type 1 Diabetes Mellitus
Interventions
Promoting Resilience in Stress Management (PRISM)
Behavioral
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
13 Years to 18 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Houston, Texas • Seattle, Washington
Completed Not applicable Interventional Results available

Self-Management in Young Adults With Type 1 Diabetes

NCT04975230
Conditions
Type 1 Diabetes
Interventions
Sleep Self-Management
Behavioral
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years to 26 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Type 1 Diabetes Mellitus
Interventions
BCG, Saline
Biological
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Type 1 Diabetes Mellitus, Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
12 Years to 18 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Kansas City, Missouri
Recruiting Not applicable Interventional Accepts healthy volunteers

Finding Immune Nascent Type 1 Diabetes

NCT07663136
Conditions
Healthy Adult, Type 1 Diabetes (T1D)
Interventions
phone call, email/mail
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
1 Year to 99 Years
Enrollment
3,800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Type 1 Diabetes (T1D)
Interventions
Sotagliflozin Low Dose, Sotagliflozin High Dose, Dual Continuous Glucose and Ketone Monitor
Drug · Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
La Jolla, California
Conditions
Type1diabetes
Interventions
very low carbohydrate diet, standard carbohydrate diet
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Years to 40 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Type 1 Diabetes
Interventions
Acipimox, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
25 Years to 59 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Type 1 Diabetes Mellitus
Interventions
The 3Ms Intervention
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
10 Years to 15 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
7
States / cities
Chicago, Illinois • Detroit, Michigan • Royal Oak, Michigan
Conditions
Diabetes Mellitus
Interventions
AC2993 (exenatide), daclizumab (immunosuppressive)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Not applicable Interventional Results available

Fuzzy Logic Automated Insulin Regulation

NCT03040414
Conditions
Type 1 Diabetes Mellitus
Interventions
MedtronicMinimed 670G 3.0 hybrid closed loop system, Medtronic Minimed 670G 4.0 AHCL with Guardian Sensor (3) continuous glucose monitoring sensor.
Device
Lead sponsor
HealthPartners Institute
Other
Eligibility
14 Years to 30 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
New Haven, Connecticut • Gainesville, Florida • Boston, Massachusetts + 1 more
Conditions
Hypoglycemia, Diabetes Mellitus, Type 1
Interventions
dasiglucagon, GlucaGen
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years to 70 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Orlando, Florida • Meridian, Idaho
Conditions
Type 1 Diabetes
Interventions
670G and 770G Insulin Pump, Subject's Current Diabetes Therapy
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
2 Years to 80 Years
Enrollment
959 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
25
States / cities
La Jolla, California • Palo Alto, California • Sacramento, California + 21 more
Conditions
Diabetes Mellitus, Type 1
Interventions
Methyldopa
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 46 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Aurora, Colorado
Completed No phase listed Observational Accepts healthy volunteers Results available

Prospective Study of the Impact of Insulin Pump Therapy in Young Children With Type 1 Diabetes

NCT00727220
Conditions
Type 1 Diabetes
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
1 Year to 5 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2004
U.S. locations
1
States / cities
Indianapolis, Indiana
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes

NCT00308308
Conditions
Diabetes, Type I
Interventions
Technosphere Insulin, Active comparator
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
589 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
61
States / cities
Mobile, Alabama • Chandler, Arizona • Chula Vista, California + 48 more
Completed Not applicable Interventional Results available

Extended Bolus for Meals in a Closed-loop System

NCT05454891
Conditions
Type 1 Diabetes
Interventions
Tandem t:slim X2 insulin pump: Extended bolus of insulin then standard bolus of insulin, Tandem t:slim X2 insulin pump: Standard bolus of insulin then extended bolus of insulin
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
13 Years to 19 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Francisco, California
Conditions
Ulcerative Colitis (Disorder)
Interventions
Hydroxychloroquine, Mesalamine
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia • New York, New York
Conditions
Type 1 Diabetes
Interventions
Definity microbubbles
Drug
Lead sponsor
University of Virginia
Other
Eligibility
12 Years to 18 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Charlottesville, Virginia